Other Liver Disease Steatosis/NAFLD/NASH
Other Infections
AASLD 2017: Women with Fatty Liver Disease at Higher Risk for Heart Disease
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Wednesday, 13 December 2017 00:00
- Written by Liz Highleyman
Women with non-alcoholic fatty liver disease (NAFLD) had a higher risk of cardiovascular events including chest pain and heart failure compared to women without the condition -- and about the same risk as men with NAFLD -- in a study presented at the 2017 AASLD Liver Meeting in October in Washington, DC.
AASLD 2017: Experimental NASH Therapy Improves Liver Fat and Fibrosis
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Wednesday, 01 November 2017 00:00
- Written by Liz Highleyman
GS-0976, an acetyl-CoA carboxylase (ACC) inhibitor being developed by Gilead Sciences, led to significant reductions in liver fat accumulation and fibrosis in people with non-alcoholic steatohepatitis (NASH), according to Phase 2 study results presented at the 2017 AASLD Liver Meeting last week in Washington, DC.
EASL 2015: Milk Thistle May Improve Steatohepatitis, Capsaicin from Chili Peppers Helps Fibrosis
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Wednesday, 13 May 2015 00:00
- Written by Liz Highleyman
People who used silymarin, derived from the milk thistle plant, experienced a resolution of non-alcoholic steatohepatitis (NASH) and a reduction in liver fibrosis in a randomized, placebo-controlled trial, researchers reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Another study found that dietary capsaicin, derived from chili peppers, was associated with improvement in mice with artificially induced fibrosis, the precursor to cirrhosis.
Cenicriviroc May Reduce Fibrosis in People with Fatty Liver Disease
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
Cenicriviroc, a drug that blocks both CCR5 and CCR2 receptors on immune cells, was associated with a decrease in liver fibrosis in people with non-alcoholic steatosis, a type of fatty liver disease, according to a report in the August 17 online edition of Hepatology.
Ezetimibe Did Not Reduce Liver Fat in NASH Trial, New Therapies Under Study
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Thursday, 29 January 2015 00:00
- Written by HIVandHepatitis.com
Ezetimibe (Zetia) did not perform significantly better than placebo in reducing liver fat among people with non-alcoholic steatohepatitis (NASH), according to a report in the December 6 edition of Hepatology. In related news, the FDA has designated Tobira's cenicriviroc -- also active against HIV -- as a fast-track therapy for NASH and Gilead Sciences announced a partnership to enter the NASH arena.
AASLD 2016: When You Eat May Contribute to Fatty Liver Disease as Much as What You Eat
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Monday, 14 November 2016 00:00
- Written by Liz Highleyman
People who skip breakfast and eat late at night may have an elevated risk of non-alcoholic fatty liver disease (NAFLD), according to research presented at the AASLD Liver Meeting this week in Boston. This suggests that meal timing and frequency of meals may be modifiable risk factors for fatty liver disease, which can lead to cirrhosis and liver cancer.
EASL 2014: Fatty Liver Disease Is a Risk Factor for Heart Disease and Diabetes
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Thursday, 10 April 2014 00:00
- Written by EASL
Non-alcoholic fatty liver disease is associated with increased risk of cardiovascular disease, as indicated by atherosclerosis of the carotid artery, according to a study presented at the 49thEASL International Liver Congress (EASL 2014) this week in London. A related study found that fatty liver is also associated with diabetes, and reduction of liver fat lowers diabetes risk.
AASLD 2015: Coffee Linked to Reduced Liver Fibrosis in People with HBV, HCV, and NAFLD
- Details
- Category: Fibrosis & Cirrhosis
- Published on Wednesday, 25 November 2015 00:00
- Written by Liz Highleyman
Drinking coffee was associated with lower liver stiffness -- a non-invasive measure used to estimate liver fibrosis -- in people with hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD), researchers reported at the 2015 AASLD Liver Meeting last week in San Francisco. The study also showed a trend toward less liver fat build-up in people with NAFLD.
Web Design and Development by